Veristat Congratulates TESARO on the FDA Approval of ZEJULA™
SOUTHBOROUGH, MA – May 30, 2017 – Veristat, a full service Clinical Research Organization (CRO),...
Veristat Acknowledged for its Rapid Growth on the Inc. 5000 List of America’s Fastest-Growing Private Companies
Veristat Continues To Be Recognized for Its Positive Impact & Company Growth
SOUTHBOROUGH, MA –...
Veristat Article “Adaptive Designs- Recent Advancement in Clinical Trials” Published in “Journal of Bioanalysis & Biostatistics”
Two of Veristat’s statistical and adaptive design experts submitted a research paper which was...
Veristat Strengthens Statistical Consulting and Adaptive Design Trial Expertise With Appointment of Mark Chang
Appoints Mark Chang as Senior Vice President of Strategic Statistical Consulting
SOUTHBOROUGH,...
Veristat Expands Its Clinical Operations into Europe - Acquires UK-based CRO, Spero Oncology
SOUTHBOROUGH, MA – May 2, 2016 – Veristat, a full service Clinical Research Organization (CRO),...
Veristat Ranked #35 on Boston Business Journal’s “Fast 50” List, the Top 50 Fastest Growing Private Companies in Massachusetts
Veristat Recognized as One of the Top 50 Fastest-Growing Private Companies in Massachusetts
Veristat Named as One of the Fastest Growing Private Companies in Massachusetts by Boston Business Journal
Veristat joins the Boston Business Journal’s 2016 Fast 50 (Formerly Pacesetters) list. This is the...
Veristat Strengthens Senior Management Team: Appoints Faith Haines Kolb as Vice President, Biometrics
SOUTHBOROUGH, MA – March 08, 2016 – Veristat, a full service Clinical Research Organization (CRO),...
Veristat participates in Cycle for Survival 2016 and raises over $20,000 to fund rare cancer research.
Veristat Raises over $20,000 to Support Rare Cancer Research
On Saturday, February 27th, Team...
Veristat Rides in Cycle for Survival 2016 Event to Raise Money to Fight Rare Cancers
Veristat Supports the Upcoming Boston Cycle for Survival Event Join Veristat in the Fight Against...
Veristat and Cidara Therapeutics Collaborate with a Preferred Provider Agreement
Veristat to Assist Cidara with Its Trials for Novel Echinocandin Antifungal CD101